bluebird bio has produced updated data from its gene therapy for the rare genetic neurological disease cerebral adrenoleukodystrophy (CALD), showing that it continues to work in the long-te
bluebird bio is pricing its thalassaemia gene therapy Zynteglo at €1.57 million ($1.8 million) in Europe, but with an outcomes-based payment scheme to try to persuade healthcare systems to
Doug Danison, vice-president, head of access, value and evidence strategy at bluebird bio, a gene therapy company, looks at the obstacles, opportunities and required change in thinking need
bluebird bio has its first ever product approval, getting a green light from the EMA for Zynteglo, its ex vivo gene therapy for the rare blood disorder beta thalassaemia.
